Jelovac Izabela, Bordoy Catalina
CREPP-University of Liege, Boulevard de Rectorat 7(B31), 4000 Liege, Belgium.
Int J Health Care Finance Econ. 2005 Mar;5(1):5-21. doi: 10.1007/s10754-005-6599-x.
In this paper we investigate the implications of permitting parallel imports of pharmaceuticals produced by a monopoly, from one country to another. We use a model where countries differ in the patients' level of co-payment for buying pharmaceuticals, and patients differ in the utility obtained from the consumption of pharmaceuticals. We show that the effects of parallel imports on total welfare are as follows: On the one hand, when countries differ in their health system only, parallel imports decrease total welfare; On the other hand, when countries differ in the health needs of their patients only, parallel imports enhance total welfare.
在本文中，我们研究了允许垄断企业生产的药品从一个国家平行进口到另一个国家的影响。我们使用了一个模型，其中不同国家患者购买药品的自付费用水平存在差异，并且患者从药品消费中获得的效用也有所不同。我们表明，平行进口对总福利的影响如下：一方面，当国家仅在卫生系统方面存在差异时，平行进口会降低总福利；另一方面，当国家仅在患者的健康需求方面存在差异时，平行进口会提高总福利。
